Search

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

… Thursday, February 9, 2017 Summary Three leaders in precision oncology at MSK have released a State of the Union-style report on where the field is going. Learn how we’re already helping people with cancer, and how we’re uniquely prepared to address the many challenges that still remain in the field.

Metastasis remains the primary challenge to reducing cancer deaths worldwide. A new MSK study is providing unique insights that researchers say point to new therapeutic opportunities.

… Wednesday, October 30, 2024 Metastasis remains the primary challenge to reducing cancer deaths worldwide, says Memorial Sloan Kettering Cancer Center (MSK) gastrointestinal oncologist Karuna Ganesh, MD, PhD .  That’s when a primary tumor — colorectal cancer, for example — spreads to a new part of the

The historic clinical trial is a global effort between Obafemi Awolowo University, Lagos University Teaching Hospital, and Medserve in Nigeria and Memorial Sloan Kettering Cancer Center in the United States.

… Wednesday, February 4, 2026 A ground-breaking clinical trial aimed at transforming treatment options for patients with colorectal cancer in Nigeria is actively enrolling patients after gaining official approval by the National Health Research Ethics Committee (NHREC) and the National Agency for Food

Memorial Sloan Kettering researchers are studying how drugs that reverse malfunctioning proteins may treat disease.

… Tuesday, August 3, 2021 Sloan Kettering Institute scientist Gabriela Chiosis , a member of the Chemical Biology Program , has devoted her research to studying how proteins take shape and interact with each other and how it can lead to disease when these proteins go awry. On August 3, 2021, she published

Cancer treatment is complex. For every type of cancer, there is a range of treatments, side effects, and outcomes. Machine learning can help make sense of these variables, according to Quaid Morris.

… Saturday, January 1, 2022 By Julie Grisham Cancer treatment is complex. For every type of cancer, there is a range of treatments, side effects, and outcomes — both short-term and those that arise years later. Machine learning can help make sense of these variables, according to Sloan Kettering Institute

As an autoimmune disease, Type 1 diabetes raises important questions about immune cell activity that have broad implications for immunotherapy.

… Tuesday, November 30, 2021 To an immunologist, autoimmune diseases like Type 1 diabetes are the polar opposite of cancer. In the former, the immune system goes into overdrive and attacks the body’s own organs in a relentless manner, eventually causing disease; with cancer, the immune system shuts down

A recent study led by investigators at MSK and published in Nature Medicine, included a comprehensive analysis of non relapse mortality after CAR T cell therapy in patients with lymphoma and multiple myeloma across multiple clinical trials and real-world studies. In this Q&A we discuss the study's key findings and a new tool for assessing infection risk prior to CAR T cell therapy.

… Monday, July 8, 2024 A Q&A with MSK Visiting Investigator and Research Fellow Dr. Kai Rejeski CAR T cell therapy against CD19 and B cell maturation antigen (BCMA) is a potent immunotherapy for treating advanced B cell malignancies. It comes with a unique toxicity profile that includes cytokine release

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, June 22, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Selwyn M. Vickers, MD, FACS, President and CEO Selwyn Vickers Named Among 50 Most Influential Clinical Executives by Modern Healthcare Selwyn M. Vickers, MD, FACS , President and

Seventeen scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 17, 2023, as part of Memorial Sloan Kettering’s 44th annual academic convocation.

… Monday, May 15, 2023 This year 17 scientists who did their training at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) are poised to receive their doctorates, the highest number ever to graduate from GSK in a single year. Their years of dedication and training will be recognized

… Wednesday, February 11, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Maximilian Merz Awarded $2.3 Million From the Hector Foundation  Maximilian Merz Maximilian Merz, MD, mmyeloma specialist, has been  awarded $2.3 million by the Hector Foundation